Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantation
Marras TK, Chan CK, Lipton JH, Messner HA, Szalai JP, Laupacis A. Bone Marrow Transplant. 2004; 33(5):509-17.
Publications
Changes in prescribing patterns following publication of the ALLHAT trial
Austin PC, Mamdani MM, Tu K, Zwarenstein M. JAMA. 2004; 291(1):44-5.
Quality of Cardiac Care in Ontario: EFFECT (Enhanced Feedback for Effective Cardiac Treatment)
Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000
Pilote L, Beck CA, Karp I, Alter D, Austin P, Cox J, Humphries K, Jackevicius C, Richard H, Tu JV; Canadian Cardiovascular Outcomes Research Team. Can J Cardiol. 2004; 20(1):61-7.
Impact of socioeconomic status on cardiovascular outcomes in Canada
Alter DA, Brandes S, Irvine J, Iron K. Expert Rev Pharmacoecon Outcomes Res. 2003; 3(6):691-702.
Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach
Laupacis A, Paterson JM, Mamdani M, Rostom A, Anderson GM. CMAJ. 2003; 169(11):1167-70.
Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model
Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. JAMA. 2003; 290(19):2581-7.
Canadian cardiovascular hospitalization rates and length of stay
Hall R. Healthc Q. 2003; 7(1):22-4.
The use of fixed- and random-effects models for classifying hospitals as mortality outliers: a Monte Carlo assessment
Austin PC, Alter DA, Tu JV. Med Decis Making. 2003; 23(6):526-39.
Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001
Jackevicius CA, Tu K, Filate WA, Brien SE, Tu JV; Canadian Cardiovascular Outcomes Research Team. Can J Cardiol. 2003; 19(12):1359-66.